USPTO trademark

OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)

RegisteredUSPTOWord and designClass 5

"OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)" is a word and design mark owned by Bristol-Myers Squibb Company, filed at the USPTO on April 1, 2022. It is registered and covers class 5 (Pharmaceuticals).

View Bristol-Myers Squibb Company portfolioGet this data via the API
Official USPTO record
OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW) trademark as filed
As filed with the USPTO
Status
Registered
Since August 8, 2023
Filed
April 1, 2022
Registered
August 8, 2023
Expires
Not recorded
Application no.
97342302
Registration no.
7130293
Office
USPTO
United States Patent and Trademark Office
Mark type
Word and design
1 class
Ownership

Who owns OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Bristol-Myers Squibb Company

BMY · Princeton, United States

5,160 trademarks in the portfolioView company

Representative

Marilyn F. Kelly

Bristol-Myers Squibb Company

Goods and services

What the mark covers

The products and services OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW) is filed for, grouped by Nice class.

  • Pharmaceutical preparations for human use comprising monoclonal antibodies for the treatment and prevention of cancer

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Notice of registration confirmation emailed
  2. Registered-principal register
  3. Teas change of correspondence received
  4. Applicant/correspondence changes (non-responsive) entered
  5. Teas change of owner address received
  6. Official gazette publication confirmation e-mailed
  7. Published for opposition
  8. Notification of notice of publication e-mailed
  9. Approved for pub - principal register
  10. Examiner's amendment entered

10 earlier steps on the official record.

FAQ

About OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)

Who owns the trademark "OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)"?

The USPTO trademark "OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)" (application 97342302) is owned by Bristol-Myers Squibb Company.

What is the status of "OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)"?

Its status at the USPTO is: registered.

When was "OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)" registered?

It was registered on August 8, 2023.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW) and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d2a62-2f10-7468-89ae-ccd87998974d
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d2a62-2f10-7468-89ae-ccd87998974d",
  "object": "trademark",
  "mark_text": "OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)",
  "status": {
    "primary": "active",
    "stage": "registered"
  },
  "office_code": "US",
  "application_number": "97342302",
  "filing_date": "2022-04-01",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "Bristol-Myers Squibb Company",
      "entity_id": "ent_019f2853-4217-73ff-890d-f99444b1333e"
    }
  ]
}